Efectos de los agonistas del GLP-1R en los factores de riesgo cardiovascular El mecanismo detrs del beneficio en la salud cardiovascular de los GLP1-RA no ha sido esclarecido totalmente, pero se plantea que pueda ser debido al control de factores de riesgo cardiovascular o a otros mecanismos no reconocidos previamente
Phase 2 clinical trials involved 338 adults with obesity (BMI 30 or more) and overweight (BMI of 2729.99) with one or more weight-related conditions such as high blood pressure, high cholesterol levels, heart disease, and type 2 diabetes
Given the substantial weight loss retatrutide produces, it is plausible that nutritionally driven hair shedding may occur in some individuals though this should be understood as a hypothesis based on the known effects of rapid weight loss rather than a confirmed drug-specific effect
Neutral for MACE composite and ischemic stroke (directionally favorable but not statistically significant)
2.4 Measurement of cAMP production HEK293-SNAP-GLP-1R cells were resuspended in serum-free medium and treated at 37C with indicated concentration of agonist for 30 min
Additionally, individuals who experience medical conditions such as diabetes or hypertension related to obesity may find this program particularly beneficial
